Clinical characteristics and analysis of risk factors for disease progression of patients with SARS-CoV-2 Omicron variant infection: A retrospective study of 25207 cases in a Fangcang hospital

Ying-hao, Pei; Yuan-yuan, Gu; Zhang, Haidong; Chen, Qiuhua; Xue-ran, Gu; Zhou, Hongyan; Hua, Jiang

doi:10.3389/fcimb.2022.1009894

Cited by 13 publications

(14 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, it was demonstrated that old age is an independent risk factor associated with prolonged viral shedding duration, which was in line with previous studies 36,37 . However, a retrospective study on a large sample of Fangcang hospital cases infected by the SARS‐CoV‐2 omicron variant showed that age, fever, cough, fatigue, and comorbidity are predictors for the deterioration of SARS‐CoV‐2 omicron variant infection 38 . In that study, different from ours, the researchers compared the clinical characteristics between non‐severe patients and severe patients, and identified the risk factors for severe COVID‐19 infection.…”

Section: Discussionsupporting

confidence: 87%

Clinical and virological features of asymptomatic and mild symptomatic patients with SARS‐CoV‐2 Omicron infection at Shanghai Fangcang shelter hospital

Zhang,

Kang,

Wang

et al. 2023

Immunity Inflam & Disease

View full text Add to dashboard Cite

ObjectiveThe objective of this study is to evaluate and compare clinical and virological characteristics of asymptomatic and mild symptomatic patients of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) Omicron BA.2.2 variant infection and identify risk factors associated with the prolonged viral negative conversion duration.MethodsWe conducted a retrospective observational study in a Shanghai (China) Fangcang shelter hospital from April 9 to May 17, 2022. The patient‐related demographic or clinical data were retrospectively recorded. Comparisons of demographic and clinical characteristics between asymptomatic and mild‐symptomatic patients were performed. Cox regression was performed to identify the risk factors of prolonged viral negative conversion duration.ResultsA total of 551 patients confirmed with SARS‐CoV‐2 Omicron variant infection were enrolled in the study. Of these, 297 patients (53.9%) were asymptomatic and 254 patients (46.1%) had mild symptoms. When comparing the clinical and virological characteristics between the asymptomatic and mild symptomatic groups, several clinical parameters, including age, gender, time to viral clearance from the first positive swab, chronic comorbidities, and vaccination dose did not show statistically significant differences. In mild symptomatic patients, the median viral negative conversion duration (NCD) was 7 days (interquartile range [IQR]: 5–9), which was comparable to the median of 7 days (IQR: 5–10) in asymptomatic patients (p = .943). Multivariate Cox analysis revealed that patients age ≥ 60 years had a significantly higher hazard ratio (HR) for prolonged viral NCD (HR: 1.313; 95% confidence interval: 1.014–1.701, p = .039).ConclusionAsymptomatic and symptomatic patients with non‐severe SARS‐CoV‐2 Omicron BA.2.2 variant infection have similar clinical features and virological courses. Old age was an independent risk factor for prolonged SARS‐CoV‐2 conversion time.

show abstract

Section: Discussionsupporting

confidence: 87%

Clinical and virological features of asymptomatic and mild symptomatic patients with SARS‐CoV‐2 Omicron infection at Shanghai Fangcang shelter hospital

Zhang,

Kang,

Wang

et al. 2023

Immunity Inflam & Disease

View full text Add to dashboard Cite

show abstract

“…Our results are consistent with an observational study that the majority of patients infected with the SARS-CoV-2 Omicron variant are asymptomatic or mild COVID-19 [11], suggesting a reduced pathogenicity of Omicron variants [12,13]. Nevertheless, the unique biological characteristics of Omicron variants increase the transmissibility, particularly in asymptomatic COVID-19 patients [14].…”

Section: Discussionsupporting

confidence: 91%

Oral Azvudine (FNC) Tablets in Patients infected with SARS-CoV-2 Omicron Variant: A Retrospective Cohort Study

Chen

Hong

et al. 2023

Preprint

View full text Add to dashboard Cite

Background: There is a lack of data on the efficacy of oral Azvudine in Coronavirus Disease treatment. This study aimed to assess the association between Azvudine treatment and clinical outcomes in a cohort of patients infected with the SARS-CoV-2 Omicron variant. Methods: This is a retrospective study conducted in two mobile cabin hospitals. All consecutive patients with a diagnosis of COVID-19 admitted from August to October 2022 were included in the study. Linear regression models and Cox proportional hazards models were used to assess the association between Azvudine treatment and time to obtain the first negative nucleic acid test results. Results: A total of 207 patients were analyzed, of whom 166 patients (80.2%) received Azvudine treatment after hospitalization, and the rest did not. Linear regression models showed that Azvudine treatment was associated with reduced time to obtain the first negative nucleic acid test results after adjusting for age and gender [mean difference = -1.658; 95% CI: -2.772 to -0.544, P = 0.0039]. The multivariable Cox analysis conforms to the results from the linear regression model (hazard ratio = 1.461; 95% CI: 1.01 to 2.11, P = 0.044). Conclusion: Azvudine treatment was associated with reduced virus shedding time. Further studies are needed to confirm our findings.

show abstract

“…Hospitalization rate, hospitalization length, and death rate of patients infected with omicron variant have declined relative to those infected with other variants, and the symptoms are less severe [6][7][8]. However, omicron has more than 50 mutations and different amino acids in the spike protein, which poses a large threat to elderly patients with no vaccination and chronic comorbidities owing to the disordered immune system, making treatment difficult for these patients [4,9,10]. It has been reported that the omicron variant is resistant to the treatment of convalescent plasma and most neutralizing nonoclonal antibodies [11].…”

Section: Introductionmentioning

confidence: 99%

Safety and Efficacy of Paxlovid Against Omicron Variants of Coronavirus Disease 2019 in Elderly Patients

et al. 2023

View full text Add to dashboard Cite

Introduction Elderly patients are the most affected and vulnerable to COVID-19 and effective therapeutic interventions are urgently required. We clarified the safety and efficacy of Paxlovid in the treatment of elderly patients with coronavirus disease 2019 (COVID-19). Methods Patients aged over 60 years and with mild to moderate COVID-19 were admitted to the Zhongshan Hospital MinHang MeiLong Branch, Fudan University and received either Paxlovid treatment or only conventional therapy, between April 1 and May 31, 2022. Viral shedding time, duration of hospital stay, disease progression, and adverse events were analyzed, and multivariate Cox regression analysis was performed to detect the independent high-risk factors for COVID-19 progression in the patients. Results A total of 163 (82 and 81 in the treatment and control groups, respectively) patients had a median age of 82 (71–89) years, and 89.0% had at least one concomitant disease. The duration of hospitalization reduced from 15 to 13 days, and viral shedding time reduced from 20 to 16.5 days after Paxlovid treatment. The differences of these two variables between the groups were significant ( p < 0.01). Moreover, no serious adverse events or obvious changes in laboratory test results were observed in patients treated with Paxlovid. One patient (1.2%) treated with Paxlovid experienced rebound 56 days after negative measurement. Multivariate analysis showed that Paxlovid therapy, age, hemoglobin, and nucleic acid Ct values at admission were independent risk factors for hospitalization within 14 days, and the differences were significant ( p < 0.01). Conclusion The use of Paxlovid in elderly patients may promote recovery from COVID-19 and reduce the viral load without adverse events. Clinical trial registration www.ClinicalTrials.gov , ID: ChiCTR2200066990. Supplementary Information The online version contains supplementary material available at 10.1007/s40121-023-00760-x.

show abstract

Clinical characteristics and analysis of risk factors for disease progression of patients with SARS-CoV-2 Omicron variant infection: A retrospective study of 25207 cases in a Fangcang hospital

Cited by 13 publications

References 33 publications

Clinical and virological features of asymptomatic and mild symptomatic patients with SARS‐CoV‐2 Omicron infection at Shanghai Fangcang shelter hospital

Clinical and virological features of asymptomatic and mild symptomatic patients with SARS‐CoV‐2 Omicron infection at Shanghai Fangcang shelter hospital

Oral Azvudine (FNC) Tablets in Patients infected with SARS-CoV-2 Omicron Variant: A Retrospective Cohort Study

Safety and Efficacy of Paxlovid Against Omicron Variants of Coronavirus Disease 2019 in Elderly Patients

Contact Info

Product

Resources

About